GlassScriptPhysician profile
George Sadek
NPI 1851918254
$2,575.12
in general payments reported to CMS, 2019-2025
21 companies · $101 in 2025
The $101 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $355 · 2022: $652 · 2023: $687 · 2024: $780 · 2025: $101.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,568.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,568.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $388.50 | 2022-2024 | Farxiga, Wainua, Andexxa |
| Emd Serono, INC. | $237.94 | 2022-2025 | Mavenclad |
| Ucb, INC. | $233.67 | 2023-2024 | Briviact |
| Takeda Pharmaceuticals U.S.A., INC. | $185.97 | 2022-2024 | Entyvio |
| Abbvie INC. | $166.32 | 2021-2023 | Botox |
| Horizon Therapeutics Plc | $164.30 | 2022-2023 | Uplizna |
| Averitas Pharma INC. | $153.42 | 2023-2024 | Qutenza |
| Genentech USA, INC. | $139.65 | 2022-2024 | Ocrevus, Enspryng |
| Lilly USA, LLC | $134.06 | 2022-2024 | Amyvid |
| Novartis Pharmaceuticals Corporation | $126.93 | 2024 | |
| Biogen, INC. | $110.68 | 2021-2022 | |
| Jazz Pharmaceuticals INC. | $90.00 | 2023-2024 | Epidiolex |
| Pfizer INC. | $75.23 | 2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $74.68 | 2022 | |
| Alexion Pharmaceuticals, INC. | $73.39 | 2021-2024 | Ultomiris |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $57.00 | 2022-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $54.98 | 2024 | Xifaxan |
| Biohaven Pharmaceuticals, INC. | $46.29 | 2021 | |
| Lundbeck LLC | $23.82 | 2021 | |
| Eisai INC. | $19.23 | 2022 | |
| Argenx US, INC. | $19.06 | 2023 | Vyvgart |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw George Sadek listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.